fbbva-jurado-biomedicina-delamarre

Lélia Delamarre

JURY MEMBER

Biomedicine

9th edition

Group leader in the Department of Cancer Immunology at biotech company Genentech (United States).

BIO

Her research focuses on the modulation of dendritic and T-cell functions.

Her group recently contributed to the identification of cancer mutations (or neoantigens) as drivers of tumor immunity, and developed a novel strategy to select neoantigen candidates that combine whole genome sequencing and mass spectrometry, along with structural prediction.

Neoantigens are now being used for the development of immune monitoring tools in cancer immunotherapy, and the design of novel vaccines.